BHVN - BIOHAVN PHRMCTCL ()

BHVNのニュース

   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
   Here''s Why Biohaven Pharmaceutical Is Soaring Today  2021/07/07 16:07:35 The Motley Fool
Preliminary sales figures for the company''s new migraine drug were much better than expected.
   Jim Cramer Says People Need To Know About Biohaven  2021/07/07 14:58:32 Benzinga
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) announced Wednesday that it has preliminary net revenue of approximately $93 million for its NURTEC ODT product in the second quarter of 2021. NURTEC ODT is an oral drug for the preventive treatment of episodic migraine. It''s now the only migraine medication approved to treat both acute migraine attacks and help prevent future migraine attacks. NURTEC ODT has Full story available on Benzinga.com
   Hedge Funds Are Dumping Biohaven Pharmaceutical Holding Company Ltd. (BHVN)  2021/07/06 13:43:44 Insider Monkey
   Biohaven adds Kishen Mehta to board of directors  2021/06/17 20:05:08 Seeking Alpha
   Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares  2021/03/16 02:16:00 PR Newswire
NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting…
   Biohaven Announces Proposed Public Offering Of Common Shares  2021/03/15 20:32:00 PR Newswire
NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting…
   Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine  2021/03/10 12:30:00 PR Newswire
NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma announced today that NURTEC® ODT (rimegepant) was approved by the Israeli Ministry of Health for the acute treatment of migraine with and without aura…
   Leerink Partners Stick to Their Buy Rating for Biohaven Pharmaceutical Holding Co Ltd By Investing.com  2021/03/02 14:48:16 Investing.com
Leerink Partners Stick to Their Buy Rating for Biohaven Pharmaceutical Holding Co Ltd
   Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments  2021/03/01 12:30:00 PR Newswire
NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including…
   Biohaven Pharmaceutical (NYSE:BHVN) Price Target Raised to $110.00  2020/11/20 07:54:43 Transcript Daily
Biohaven Pharmaceutical (NYSE:BHVN) had its price target boosted by Canaccord Genuity from $80.00 to $110.00 in a research report report published on Monday, The Fly reports. They currently have a buy rating on the stock. A number of other research analysts also recently weighed in on the stock. Wedbush upped their price objective on shares […]
   Recap: Biohaven Pharmaceutical Q3 Earnings  2020/11/09 08:32:00 Benzinga
Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per …
   Gregory Bailey Sells 3,748 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock  2020/10/23 02:18:45 Daily Political
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 3,748 shares of Biohaven Pharmaceutical stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $78.88, for a total transaction of $295,642.24. Following the sale, the director now owns 2,585,181 shares in the company, valued at $203,919,077.28. The […]
   Gregory Bailey Sells 4,554 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock  2020/10/21 22:42:45 US Banking News
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 4,554 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $78.98, for a total value of $359,674.92. Following the completion of the sale, the director now directly owns 2,585,181 shares in […]
   Biohaven Pharmaceutical : 2Q Earnings 2020 | MarketScreener  2020/08/10 13:44:07 MarketScreener
2nd Quarter 2020 Earnings August 10, 2020 Ellie, living with migraine … | August 10, 2020

calendar